Search for Nicotine-Like Receptor Binding Sites in Brain

  • A. Nordberg
  • C. Larsson
Part of the Advances in Behavioral Biology book series (ABBI, volume 25)


Our knowledge of nicotine-like receptors in brain, their distribution and functional importance is fragmentary. Most information has been obtained by using iontophoretic and electrophysiological techniques. The introduction of radio-receptor binding techniques has, however, increased the possibility of characterizing the nicotine-like binding sites in brain by using ligands with high specific radioactivity. It is well established that α-bungarotoxin (α-Btx) binds to the nicotine-like acetylcholine (ACh) receptor on electric organ of electric eel and ray and on skeletal muscle and functionally acts as an irreversible antagonist. Binding of α-Btx to various nervous tissues such as sympathetic ganglia, retina and brain have been reported (for review, see 5), but it has not yet been proved that this binding is to a functionally active ACh receptor binding site (2,3,8). For nicotine receptor binding studies in brain, α-Btx has been used by most investigators (5), but in a few studies other ligands such as nicotine (1,7,10,17), and the nicotinic antagonist tubocurarine (1,7) have been used.


Sympathetic Ganglion Receptor Binding Site Electric Organ Human Fetal Brain Human Hippocampus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abood, L.G., Tometsko, A. and MaeNeil, M. (1979): Arch. Int. Pharmacodyn. 237:213–229.Google Scholar
  2. 2.
    Ben-Barak, J. and Dudai, Y. (1979): Brain Res. 166:245–257.CrossRefGoogle Scholar
  3. 3.
    Carbonetto, S.T., Fambrough, D.M. and Muller, K.J. (1978): Proc. Nat. Acad. Sci. 75:1016–1020.CrossRefGoogle Scholar
  4. 4.
    Eterovic, V.A. and Bennett, E.L. (1974): Biochem. Biophys. Acta 362:346–355.CrossRefGoogle Scholar
  5. 5.
    Morley, B.J., Kemp, G.E. and Salvaterra, P. (1979): Life Sci. 859–872.Google Scholar
  6. 6.
    Morley, B.J., Lorden, J.F., Brown, G.B., Kemp, G.E. and Bradley, R.J. (1977): Brain Res. 134:161–166.CrossRefGoogle Scholar
  7. 7.
    Nordberg, A. and Larsson, C. (1980): Acta Physiol. Scand. Suppl. 479:19–23.Google Scholar
  8. 8.
    Patrick, J. and Stallcup, W.B. (1977): Proc. Nat. Acad. Sci. 74:4689–4692.CrossRefGoogle Scholar
  9. 9.
    Salvaterra, P.M., Mahler, H.R. and Moore, W.J. (1975): J. Biol. Chem. 250:6469–6475.Google Scholar
  10. 10.
    Schleifer, L.S. and Eldefrawi, M.E. (1974): Neuropharmacology 13:53–63.CrossRefGoogle Scholar
  11. 11.
    Schmidt, J. (1977): Molec. Pharmacol. 13:283–290.Google Scholar
  12. 12.
    Segal, M., Dudai, Y. and Amsterdam, A. (1978): Brain Res. 148:105–119.CrossRefGoogle Scholar
  13. 13.
    Speth, R.C., Chen, F.M., Lindstrom, J.M., Kobayshi, R.M. and Yamamura, H.I. (1977): Brain Res. 131:350–355.CrossRefGoogle Scholar
  14. 14.
    Terenius, L. and Wahlstrom, A. (1976): Eur. J. Pharmacol. 40:241–248.CrossRefGoogle Scholar
  15. 15.
    Tindall, R.S.A., Kent, M., Baskin, F. and Rosenberg, R.N. (1978): J. Neurochem. 30:859–863.CrossRefGoogle Scholar
  16. 16.
    Wade, P.D. and Timiras, P.S. (1980): Brain Res. 181:381–389.CrossRefGoogle Scholar
  17. 17.
    Yoshida, K. and Imura, H. (1979): Brain Res. 172:453–459.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • A. Nordberg
    • 1
  • C. Larsson
    • 1
  1. 1.Department of PharmacologyUniversity of UppsalaUppsalaSweden

Personalised recommendations